Get the Stockscreener App
24.50
2.20%
-0.55
After Hours:
24.50
Beam Therapeutics Inc stock is traded at $24.50, with a volume of 845.11K.
It is down -2.20% in the last 24 hours and down -8.17% over the past month.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$25.05
Open:
$24.94
24h Volume:
845.11K
Relative Volume:
0.85
Market Cap:
$2.02B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-5.4324
EPS:
-4.51
Net Cash Flow:
$-153.40M
1W Performance:
-0.89%
1M Performance:
-8.17%
6M Performance:
-25.85%
1Y Performance:
+1.87%
1-Day Range:
$24.22
$25.24
1-Week Range:
$24.21
$25.95
52-Week Range:
$16.95
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy (NASDAQ:BEAM) - Seeking Alpha
American Century Companies Inc. Grows Stock Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Scientech Research LLC Acquires 32,469 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
CRISPR-PE Technology Industry Size and Revenue Analysis | Beam Therapeutics, CRISPR Therapeutics, GenScript Biotech – elektrotransports.lv - Elektrotransports.lv
ARCH Venture Management LLC Takes $127.53 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
XTX Topco Ltd Takes $745,000 Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics' (BEAM) Sector Perform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Rhumbline Advisers Buys 23,565 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Jones Trading sets Beam Therapeutics to Hold amid competition - Investing.com
Jones Trading sets Beam Therapeutics to Hold amid competition - Investing.com India
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Price Target Increased to $69.00 by Analysts at Stifel Nicolaus - Defense World
Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $69.00 at Stifel Nicolaus - MarketBeat
RNA-Based Therapeutics Market to Grow by USD 1.27 Billion (2024-2028) Due to Increased Investment and Funding, AI Trends Impacting RevenueTechnavio - The Malaysian Reserve
Alpha-1 Antitrypsin Deficiency Market Expected to Experience - openPR
Beam Therapeutics stock target raised by Stifel with Buy rating maintained - Investing.com India
Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) - Benzinga
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
CRISPR and Cas Gene Market Key Companies | AstraZeneca plc., Addgene, Beam Therapeutics, Cibus - Cauverynews
Crispr Genomic Cure Market Size, Share, Growth, Overview, - openPR
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? - Yahoo Finance
How To Trade (BEAM) - Stock Traders Daily
Top 5 CRISPR Companies To Invest In (September 2024) - Securities.io
Beam Therapeutics (NASDAQ:BEAM) Trading Down 5.9% - MarketBeat
Liontrust Investment Partners LLP Makes New $1.87 Million Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. Forecasted to Post Q3 2024 Earnings of ($0.98) Per Share (NASDAQ:BEAM) - MarketBeat
Baillie Gifford & Co. Decreases Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics' (BEAM) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics - Benzinga
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 4.2% - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Stock Holdings Cut by Sumitomo Mitsui Trust Holdings Inc. - MarketBeat
Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology - MSN
Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology - Yahoo Finance
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss - MSN
10 Stocks That Will Change the World - Insider Monkey
QRG Capital Management Inc. Reduces Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
FY2024 EPS Estimates for Beam Therapeutics Inc. Cut by Cantor Fitzgerald (NASDAQ:BEAM) - Defense World
Beam Therapeutics Inc. to Post FY2024 Earnings of ($4.62) Per Share, Wedbush Forecasts (NASDAQ:BEAM) - Defense World
When the Price of (BEAM) Talks, People Listen - Stock Traders Daily
3 Gene Editing Stocks with Potential to Transform Medicine - InvestorPlace
3 Gene Editing Stocks with Potential to Transform Medicine - Yahoo Finance
Leerink Partnrs Research Analysts Lift Earnings Estimates for Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
FY2024 Earnings Estimate for Beam Therapeutics Inc. (NASDAQ:BEAM) Issued By Cantor Fitzgerald - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) PT Raised to $48.00 at JPMorgan Chase & Co. - Defense World
Beam Therapeutics (NASDAQ:BEAM) Stock Rating Reaffirmed by Royal Bank of Canada - Defense World
Beam Therapeutics (NASDAQ:BEAM) PT Lowered to $31.00 - Defense World
California State Teachers Retirement System Sells 2,066 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Equities Analysts Offer Predictions for Beam Therapeutics Inc.’s FY2028 Earnings (NASDAQ:BEAM) - Defense World
Wedbush Weighs in on Beam Therapeutics Inc.'s FY2028 Earnings (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by GAMMA Investing LLC - Defense World
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):